Novaretti M C Z, Jens E, Pagliarini T, Bonifácio S L, Dorlhiac-Llacer P E, Chamone D A F
Hematology Department, University of São Paulo Medical School and Immunohematology Department, Fundação Pró-Sangue/Hemocentro de São Paulo, São Paulo, Brazil.
Clin Lab Haematol. 2003 Oct;25(5):311-5. doi: 10.1046/j.1365-2257.2003.00540.x.
Anti-D titration is the first step in the evaluation of the RhD-sensitized patient. Traditionally, anti-D titration has been performed by tube agglutination. Gel microcolumn assay is a method that has gained widespread usage throughout the world, mainly for ABO/Rh typing, unexpected antibody screening and direct antiglobulin tests. As gel assay has become widely used as a routine method to detect red blood cell alloantibodies, a critical anti-D titer needs to be established. Seventy-nine known blood samples with anti-D (titers 1-32) were titrated simultaneously by the conventional tube test and the gel microcolumn assay. Red blood cells (R0r phenotype) were used, with a final concentration of 3% for tube and 0.8% for gel. Serial twofold dilutions (2-2.048) were prepared for each technique, followed by reading in antiglobulin phase. Anti-D titration in the gel microcolumn assay showed significantly higher titers (mean 3.4-fold) than the conventional tube test in all samples studied. Based on these data, it was not possible to determine a critical titer for anti-D titration by the gel microcolumn assay.
抗-D滴定是评估RhD致敏患者的第一步。传统上,抗-D滴定是通过试管凝集法进行的。凝胶微柱法是一种在全世界广泛应用的方法,主要用于ABO/Rh血型鉴定、意外抗体筛查和直接抗球蛋白试验。由于凝胶法已广泛用作检测红细胞同种抗体的常规方法,因此需要确定一个关键的抗-D效价。采用传统试管法和凝胶微柱法同时对79份已知抗-D(效价为1-32)的血样进行滴定。使用红细胞(R0r表型),试管法的终浓度为3%,凝胶法为0.8%。每种技术均进行连续两倍稀释(2-2.048),然后在抗球蛋白阶段读取结果。在所有研究样本中,凝胶微柱法的抗-D滴定显示效价显著高于传统试管法(平均3.4倍)。基于这些数据,无法通过凝胶微柱法确定抗-D滴定的关键效价。